FlyMedi
Online medical tourism marketplace for comparing clinics and booking treatments abroad
Website: https://www.flymedi.com/
PUBLIC
| Attribute | Detail |
|---|---|
| Name | FlyMedi |
| Tagline | Online medical tourism marketplace for comparing clinics and booking treatments abroad |
| Headquarters | Amsterdam, Netherlands |
| Founded | 2015 |
| Business Model | Marketplace |
| Industry | Healthtech |
| Technology | Software (Non-AI) |
| Geography | Western Europe |
| Founding Team | Fatih Ciftci (Founder & CEO) [Tracxn, 2025] |
| Funding Label | Undisclosed |
Links
PUBLIC
- Website: https://www.flymedi.com/
- LinkedIn: https://ca.linkedin.com/company/flymedi
Executive Summary
PUBLIC
FlyMedi operates an online marketplace for medical tourism, connecting patients with accredited clinics abroad for treatments ranging from cosmetic surgery to chemotherapy, a model that simplifies a historically fragmented and opaque cross-border process [Flymedi.com, 2025]. The company's decade-long operation, recent corporate restructuring, and focus on a high-growth niche present a case for investor scrutiny, though its financial and operational transparency remains limited. Founded in 2015 by Fatih Ciftci, the business has evolved from its Amsterdam origins to a recent UK incorporation, suggesting a strategic shift or formalization of its corporate structure [Companies House, 2026] [Tracxn, 2025].
Its core product is a software platform that aggregates clinics, primarily in Turkey, allowing users to compare treatments, read verified patient reviews, and book all-inclusive travel packages, aiming to reduce the research and coordination burden for medical travelers [Flymedi.com, 2025]. Founder and CEO Fatih Ciftci holds degrees in Economics and an MBA, bringing several years of startup experience to the venture, though the full senior management team's operational history in healthcare or travel logistics is not detailed in public profiles [Crunchbase].
No funding rounds, valuation, or revenue metrics are publicly disclosed, which is unusual for a company of its age and complicates a standard growth profile assessment. The business model appears to be a classic marketplace, likely earning commissions on facilitated bookings, but its scale and unit economics are not confirmed. Over the next 12-18 months, key monitors will be any formal capital raise, the disclosure of partnership or customer traction metrics, and clarity on the strategic rationale behind the 2025 UK corporate filing.
Data Accuracy: YELLOW -- Core product description is confirmed by the company's own site, but founding details and corporate status rely on secondary databases with partial corroboration.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Business Model | Marketplace |
| Industry / Vertical | Healthtech |
| Technology Type | Software (Non-AI) |
| Geography | Western Europe |
| Founding Team | Fatih Ciftci |
Company Overview
PUBLIC
FlyMedi was founded in 2015 as an online medical travel service, according to its corporate profile and third-party databases [Crunchbase] [Tracxn, 2025]. The company's founding narrative, as presented on its website, centers on simplifying the complex process of arranging healthcare abroad by aggregating accredited clinics and verified patient reviews into a single marketplace [Flymedi.com]. Its initial headquarters were listed as Amsterdam, Netherlands, a detail corroborated by several early directory listings [EU-Startups] [Enterprise League].
A more recent and concrete legal development is the incorporation of FLYMEDI LIMITED as a private company in the United Kingdom on June 12, 2025 [Companies House, 2026]. This entity, registered under company number 16514988, is active and its stated nature of business includes human health activities. The relationship between the original Dutch entity and this new UK corporate vehicle is not detailed in public filings, but the move suggests an operational or strategic shift, possibly to access a different regulatory or market environment.
Founder and CEO Fatih Ciftci is identified in database profiles, which note educational backgrounds in Economics and an MBA [Tracxn, 2025] [Crunchbase]. Other named executives include Ilker Petek, listed as Chief Commercial Officer and Managing Partner, and Emre Fitologlu, listed as CMO and Managing Partner, though these roles are sourced from third-party data aggregators with lower confidence [RocketReach, 2026]. A significant, albeit soft, milestone is the accumulation of positive customer service reviews on Trustpilot, which serves as a public signal of user satisfaction and operational continuity [Trustpilot, 2026].
Data Accuracy: YELLOW -- Core founding date and recent UK incorporation are confirmed by official sources; team details and entity history rely on single or lower-confidence sources.
Product and Technology
MIXED
FlyMedi's product is a classic marketplace, connecting patients seeking affordable, accredited medical care abroad with a curated network of clinics. The platform's core function is comparison, allowing users to browse clinics, read verified patient reviews, and book all-inclusive packages that bundle treatment with travel logistics [Flymedi.com]. The company's public-facing material emphasizes Turkey as a primary destination, suggesting a focused supply-side strategy rather than a global scatter [Flymedi.com, 2025].
The technology enabling this appears to be a standard software stack for an online booking and review platform. There is no mention of proprietary AI or advanced data matching in the company's public descriptions; instead, the stated wedge is aggregation and trust-building through verified reviews and accredited partners. A recent statement from the CEO highlighted "AI and payment trust" as future game-changers in the sector, but this was framed as an industry trend rather than a specific product announcement [Financial Content / MarketersMedia, 2025]. The user journey, as outlined on the company blog, involves direct consultation with the company's "health and wellness experts," indicating a high-touch, service-oriented layer on top of the self-serve platform [Flymedi.com].
Data Accuracy: YELLOW -- Product claims are consistent across the company's own website, but technical implementation details and roadmap are not publicly disclosed.
Market Research
PUBLIC The medical tourism marketplace model addresses a persistent, high-stakes consumer need: navigating the opaque and fragmented world of cross-border healthcare with reliable information and logistical support.
Third-party market sizing for the specific online medical tourism intermediary segment is not publicly available. However, analogous data for the broader medical tourism industry provides context. The global medical tourism market was valued at approximately $104.68 billion in 2023 and is projected to reach $273.72 billion by 2030, growing at a compound annual growth rate (CAGR) of 14.7% from 2024 to 2030, according to a report from Grand View Research [Grand View Research, 2024]. This growth is driven by several converging tailwinds. Cost differentials remain the primary catalyst, with procedures in popular destinations like Turkey, Thailand, and Mexico often costing 50-80% less than in Western Europe or North America. An aging global population and rising healthcare costs in developed nations are expanding the addressable patient pool. Furthermore, the post-pandemic normalization of international travel and increased digital comfort with researching and booking complex services online have removed key behavioral barriers.
Adjacent and substitute markets shape the competitive environment. Direct-to-clinic booking, facilitated by individual hospital marketing, represents the largest substitute, though it lacks the aggregation and comparison features of a marketplace. Traditional medical tourism agencies, often regionally focused and operating via phone and email, are another substitute being digitized. The broader online travel agency (OTA) market, valued in the hundreds of billions, is a key adjacent space, demonstrating consumer willingness to book complex, high-value trips online, though it typically excludes clinical coordination.
Regulatory and macro forces introduce significant complexity. The regulatory landscape is highly fragmented, governed by the medical device and healthcare provider regulations of the destination country, the travel and consumer protection laws of the patient's home country, and international standards for patient data (like GDPR). Currency volatility can impact package pricing and margins. Geopolitical instability in key destination regions poses an intermittent risk to travel flows. The absence of universal, standardized accreditation for international clinics remains a core market friction that intermediaries aim to mitigate through their own vetting processes.
| Metric | Value |
|---|---|
| Market Size 2023 | 104.68 $B |
| Projected Size 2030 | 273.72 $B |
| CAGR (2024-2030) | 14.7 % |
The projected growth rate suggests a robust underlying demand, though the intermediary's share of this total addressable market is untested and likely a small single-digit percentage. The high CAGR indicates the tailwinds are strong enough to support multiple players, but success will hinge on capturing trust and transaction volume in specific high-flow corridors, such as the Europe-to-Turkey route FlyMedi emphasizes.
Data Accuracy: YELLOW -- Market sizing is from a single third-party analyst report for the broader industry, used as an analogous reference. Specific segment data for online marketplaces is not confirmed.
Competitive Landscape
MIXED, FlyMedi operates in a fragmented global market where its primary challenge is not a single dominant player, but a dense thicket of specialized booking platforms, direct clinic sales, and adjacent travel services.
FlyMedi’s public positioning centers on being a curated, user-friendly marketplace for medical tourism, with a pronounced focus on Turkey. The company’s direct, named competitors are other online aggregators that perform a similar matchmaking function between patients and international clinics. A comparison of these marketplace players based on available public data is below.
| Company | Positioning | Stage / Funding | Notable Differentiator | Source |
|---|---|---|---|---|
| FlyMedi | Online marketplace for comparing clinics & booking all-inclusive medical tour packages, with a focus on Turkey. | Undisclosed funding; founded 2015. | Emphasis on Turkey as a primary destination and verified patient reviews. | [Flymedi.com, 2025] |
| Bookimed | International medical tourism platform offering treatment bookings and second opinions. | Undisclosed funding; founded 2016. | Offers a medical concierge service and second medical opinions as part of its package. | [Bookimed.com] |
| MyMediTravel | Global medical tourism marketplace comparing prices and reviews for treatments abroad. | Undisclosed funding; founded 2013. | Operates a price comparison engine across a wide range of countries and procedures. | [MyMediTravel.com] |
The competitive map extends well beyond these direct marketplace analogs. The landscape can be segmented into three broad tiers. First, the incumbent clinic networks and hospital groups, particularly in key destination countries like Turkey, Thailand, and India. These providers often have their own international patient departments and direct booking channels, bypassing aggregators entirely. Second, the challenger platforms like FlyMedi, which aggregate these providers to reduce patient search costs. Third, adjacent substitutes, including specialized medical travel agencies, concierge services, and even general tourism platforms that have begun listing wellness and elective surgery packages. The lack of proprietary clinical care or owned facilities places FlyMedi squarely in the challenger aggregator tier, competing on trust, convenience, and breadth of choice.
FlyMedi’s defensible edge today appears to be its curated focus on the Turkish market, which is a leading global hub for procedures like cosmetic surgery, dental work, and hair transplants. By concentrating its provider network and content marketing on this single, high-volume destination, the company can build deeper local partnerships and more targeted patient acquisition funnels than generalist global platforms. This geographic specialization is a durable edge only if FlyMedi can achieve and maintain a dominant share of patient referrals within Turkey, a scenario that remains unverified. The edge is perishable, however, as larger platforms can easily create dedicated Turkey verticals, and Turkish clinics themselves may choose to work with multiple marketplaces to avoid dependency.
The company’s most significant exposure is its reliance on a pure marketplace model without owned inventory or capital-intensive services. This makes it vulnerable on two fronts. Distribution exposure: A key clinic partner could launch its own direct booking portal or sign an exclusive deal with a better-funded competitor, instantly removing a chunk of FlyMedi’s supply. Channel exposure: The company does not own the patient relationship end-to-end; complications during travel or treatment could damage its brand despite being a facilitator, not a provider. Furthermore, it lacks a public moat in technology,the platform is described as a non-AI software service [Flymedi.com, 2025], suggesting the user experience and backend operations are not protected by significant technical barriers.
Looking ahead 18 months, the most plausible competitive scenario is further market fragmentation followed by consolidation. The ‘winner’ will likely be the platform that successfully moves beyond lead generation to own more of the patient journey’s economics, perhaps through integrated financing, insurance, or post-operative care coordination. If FlyMedi can use its Turkish focus to secure exclusive partnerships or launch a proprietary service layer, it could emerge as a strong regional player. The ‘loser’ in this scenario would be undifferentiated global marketplaces that fail to cultivate deep local expertise or add sufficient value beyond a basic listing service, making them susceptible to being disintermediated by clinics or displaced by destination-specific specialists.
Data Accuracy: YELLOW, Competitor identification and basic positioning are confirmed via company websites. Funding stages and detailed differentiators for competitors are not publicly available from primary sources, and FlyMedi’s own competitive advantages are inferred from its stated market focus.
Opportunity
PUBLIC The core opportunity for FlyMedi is to become the dominant transaction layer for a global medical tourism market that serves millions of patients annually, a position that could command significant platform value if network effects solidify.
The headline opportunity is to establish the default discovery and booking platform for cross-border elective healthcare, starting with a stronghold in Turkey. The company's decade-long operation suggests a focus on building supplier density and a review corpus, which are critical initial steps for a marketplace. The recent UK incorporation [Companies House, 2026] could signal a strategic move to access a larger English-speaking patient base or a different regulatory environment, providing a platform for geographic expansion beyond its Amsterdam origins. The outcome is reachable because the model addresses a clear, persistent demand: patients seeking accredited, cost-effective treatments abroad who face significant information asymmetry and logistical complexity [Flymedi.com]. By aggregating verified clinics and patient reviews, FlyMedi aims to reduce that friction, a wedge that has powered other travel and services marketplaces.
Growth scenarios outline concrete paths to scale. The evidence suggests geographic and service expansion are the most plausible vectors, given the company's established focus on Turkey and the breadth of treatments listed on its platform.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Regional Hub Dominance | FlyMedi becomes the undisputed leader for medical travel to Turkey, capturing a majority of digitally-initiated patient flows. | Deepening clinic exclusivity or payment integration with top Turkish providers. | The company's content and platform are already heavily oriented toward Turkey as a primary destination [Flymedi.com, 2025]. Market leadership in a single high-volume corridor can be a profitable, defensible business. |
| Treatment Portfolio Expansion | The platform moves beyond elective aesthetics to become a trusted source for a wider range of complex, considered-care procedures like orthopedic surgeries or oncology. | Securing accreditation partnerships with major international hospital groups. | The platform's blog and service pages already cover topics like chemotherapy, indicating an intent to address broader healthcare journeys [Flymedi.com]. |
| Geographic Network Roll-up | FlyMedi replicates its Turkey marketplace model in 2-3 other high-demand medical tourism destinations (e.g., Mexico, Thailand, South Korea). | Strategic use of UK corporate entity to raise growth capital or form joint ventures. | The recent UK incorporation provides a fresh corporate vehicle potentially suited for fundraising and international expansion [Perplexity Sonar, June 2025]. |
What compounding looks like hinges on a classic two-sided marketplace flywheel. More verified patient reviews increase trust for new patients, driving more bookings. Higher patient volume improves the platform's appeal to clinics, increasing supplier density and potentially improving commercial terms for FlyMedi. This cycle can lead to a data moat: a proprietary corpus of procedure outcomes, pricing, and patient satisfaction that becomes increasingly difficult for new entrants to replicate. There is a preliminary signal of this trust-building in the form of positive customer service reviews on an independent platform [Trustpilot, 2026], suggesting the service experience can generate positive word-of-mouth, a key ingredient for the flywheel's initial turns.
The size of the win can be framed by looking at comparable transaction-based platforms in adjacent travel and healthcare services. While no direct public comparable exists for medical tourism marketplaces, platforms like Booking Holdings (for accommodation) or Zocdoc (for domestic doctor appointments) demonstrate the valuation potential of aggregated, trusted demand in fragmented service markets. A more specific scenario valuation might consider the total addressable patient flow. If, under the Regional Hub Dominance scenario, FlyMedi captured a leading share of the estimated several hundred thousand annual medical tourists to Turkey, and monetized that flow at a take-rate comparable to online travel agencies (typically 15-25%), the resulting annual platform revenue could reach the tens of millions of dollars. At a revenue multiple consistent with high-growth, capital-efficient marketplaces, this could translate to a company valuation in the low hundreds of millions of dollars (scenario, not a forecast). The key is that the opportunity is bounded and concrete, tied to capturing and monetizing a specific, measurable patient journey.
Data Accuracy: YELLOW -- The core product description and company registration are confirmed. Growth scenarios are extrapolated from the company's stated focus and corporate actions; specific traction metrics supporting the flywheel are not publicly available.
Sources
PUBLIC
[Flymedi.com, 2025] Flymedi | Compare Clinics Abroad & Affordable Treatments | https://www.flymedi.com/
[Companies House, 2026] FLYMEDI LIMITED more information - GOV.UK | https://find-and-update.company-information.service.gov.uk/company/16514988/more
[Tracxn, 2025] FlyMedi - 2025 Company Profile, Team, Funding & Competitors - Tracxn | https://tracxn.com/d/companies/flymedi/__JeDvRqm2ItwtWvMXtv3VMp1tiXytO2OlTqcU8AyrrSE
[Crunchbase] Fatih Ciftci - Founder & CEO @ FlyMedi - Crunchbase Person Profile | https://www.crunchbase.com/person/fatih-ciftci-3
[EU-Startups] FlyMedi | EU-Startups | https://www.eu-startups.com/directory/flymedi/
[Enterprise League] FlyMedi | Amsterdam, The Netherlands | Enterprise League | https://enterpriseleague.com/company/flymedi/about
[RocketReach, 2026] FlyMedi Management Team | https://rocketreach.co/flymedi-profile_b5d0c7c2f42e4b5a
[Trustpilot, 2026] FlyMedi Reviews | https://www.trustpilot.com/review/flymedi.com
[Financial Content / MarketersMedia, 2025] Flymedi CEO Highlights AI and Payment Trust as Game-Changers in Global Medical Tourism | https://markets.financialcontent.com/wral/article/marketersmedia-2025-10-2-flymedi-ceo-highlights-ai-and-payment-trust-as-game-changers-in-global-medical-tourism
[Grand View Research, 2024] Medical Tourism Market Size, Share & Trends Analysis Report, 2024 - 2030 | https://www.grandviewresearch.com/industry-analysis/medical-tourism-market
[Perplexity Sonar, June 2025] FlyMedi UK Incorporation Brief | https://www.perplexity.ai/
[Bookimed.com] Bookimed - International Medical Tourism Platform | https://bookimed.com/
[MyMediTravel.com] MyMediTravel - Compare Medical Tourism Prices & Reviews | https://www.mymeditravel.com/
Articles about FlyMedi
- FlyMedi's Marketplace Aims to Simplify Medical Travel to Turkey — The decade-old platform, which recently incorporated in the UK, connects patients with accredited clinics for cosmetic and elective procedures abroad.